Join
Live feed
·
INSIDERFilingvia Quantisnow
Keros Therapeutics Inc. logo

Director Bienaime Jean Jacques was granted 5,250 shares, increasing direct ownership by 2,625% to 5,450 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KROS· Keros Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KROS (Keros Therapeutics Inc.) and more on Quantisnow.